The role of the brain renin-angiotensin system in hypertension: Implications for new treatment

Progress in Neurobiology

Volumn 95, Issue 2, 2011, Pages 89-103

  Marc, Yannick ^a,b,c   Llorens Cortes, Catherine ^a,b,c  

^a INSERM   (France)

^b PSL RESEARCH UNIVERSITY   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Aminopeptidase A; Aminopeptidase A inhibitor; Aminopeptidase N; Angiotensin II; Angiotensin III; Angiotensin receptor subtypes; Arterial blood pressure; Brain renin angiotensin system; Hypertension; Vasopressin release; Zinc metalloproteases

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 AMINO 4 METHYLSULFONYL BUTANE THIOL; 2 AMINO PENTAN 1,5 DITHIOL; 4,4' DITHIO[BIS(3 AMINOBUTYL SULFONIC ACID)]; AMASTATIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN 1B RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN II [1 SARCOSINE 8 THREONINE]; ANGIOTENSIN III; ANTIHYPERTENSIVE AGENT; ARGIPRESSIN; BESTATIN; CANDESARTAN; EC 27; EC 33; GLUTAMYL AMINOPEPTIDASE; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; MESSENGER RNA; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; PEPTIDE HYDROLASE INHIBITOR; RB 150; SARALASIN; UNCLASSIFIED DRUG; VALSARTAN;

ADULT ANIMAL; BLOOD PRESSURE; BRAIN; BRAIN BLOOD VOLUME; BRAIN METABOLISM; BRAIN RENIN ANGIOTENSIN SYSTEM; CHEMICAL STRUCTURE; ELECTROENCEPHALOGRAM; ENZYME LOCALIZATION; HEART OUTPUT; HORMONE RELEASE; HUMAN; HYPERTENSION; IN VIVO STUDY; MOLECULAR CLONING; NERVE CELL; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN SECRETION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHETIC TONE; VASCULAR RESISTANCE;

ANGIOTENSIN III; ANIMALS; ANTIHYPERTENSIVE AGENTS; BRAIN; DRUG RESISTANCE; GLUTAMYL AMINOPEPTIDASE; HUMANS; HYPERTENSION; MOLECULAR TARGETED THERAPY; NERVE TISSUE PROTEINS; NEURONS; PROTEASE INHIBITORS; RENIN-ANGIOTENSIN SYSTEM;

EID: 80052037697     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.06.006     Document Type: Review

References (183)

1. Abhold R.H., Sullivan M.J., Wright J.W., Harding J.W. Binding, degradation and pressor activity of angiotensins II and III after aminopeptidase inhibition with amastatin and bestatin. J. Pharmacol. Exp. Ther. 1987, 242:957-962.
2. Aguilera G., Hyde C.L., Catt K.J. Angiotensin II receptors and prolactin release in pituitary lactotrophs. Endocrinology 1982, 111:1045-1050.
3. Ahmad S., Ward P. Role of aminopeptidase A activity in the regulation of the pressor activity of circulating angiotensins. J. Pharmacol. Exp. Ther. 1990, 252:643-650.
4. Allen A.M., MacGregor D.P., Chai S.Y., Donnan G.A., Kaczmarczyk S., Richardson K., Kalnins R., Ireton J., Mendelsohn F.A. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann. Neurol. 1992, 32:339-344.
5. Allen A.M., Paxinos G., Song K.F., Mendelsohn F.A.O. Localization of angiotensin receptor binding sites in the rat brain. Handbook of Chemical Neuroanatomy. Vol. 11 1992, 1-37. Elsevier, Amsterdam. A. Björklund, T. Hökfelt, M.J. Kuhar (Eds.).
6. Allen A.M., MacGregor D.P., McKinley M.J., Mendelsohn F.A. Angiotensin II receptors in the human brain. Regul. Pept. 1999, 79:1-7.
7. Allen A.M., Zhuo J., Mendelsohn F.A. Localization and function of angiotensin AT1 receptors. Am. J. Hypertens. 2000, 13:31S-38S.
8. ALLHAT Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288(23):2981-2997. Officers and Coordinators for the ALLHAT Collaborative Research Group.
9. Alliot F., Rutin J., Leenen P.J., Pessac B. Pericytes and periendothelial cells of brain parenchyma vessels co-express aminopeptidase N, aminopeptidase A, and nestin. J. Neurosci. Res. 1999, 58:367-378.
10. Andresen B.T., Shome K., Jackson E.K., Romero G.G. AT2 receptors cross talk with AT1 receptors through a nitric oxide- and RhoA-dependent mechanism resulting in decreased phospholipase D activity. Am. J. Physiol. Renal Physiol. 2005, 288:F763-F770.
11. Aronsson M., Almasan K., Fuxe A., CIntra A., Härfstrand J., Gustafsson J., Ganten D. Evidence for the existence of angiotensinogen mRNA in magnocellular paraventricular hypothalamic neurons. Acta Physiol. Scand. 1988, 132:585-586.
12. Bakris G., Bursztyn M., Gavras I., Bresnahan M., Gavras H. Role of vasopressin in essential hypertension: racial differences. J. Hypertens. 1997, 15:545-550.
13. Bargmann W., Scharrer E. The site of origin of the hormones of the posterior pituitary. Am. Sci. 1951, 39:255-259.
14. Basso N., Ruiz P., Mangiarua E., Taquini A.C. Renin-like activity in the rat brain during the development of DOC-salt hypertension. Hypertension 1981, 3(6 (Pt 2)):14-17.
15. Batt C.M., Klein E.W., Harding J.W., Wright J.W. Pressor responses to amastatin, bestatin and Plummer's inhibitors are suppressed by pretreatment with the angiotensin receptor antagonist sarthran. Brain Res. Bull. 1988, 21:731-735.
16. Benarroch E. Paraventricular nucleus, stress response, and cardiovascular disease. Clin. Auton. Res. 2005, 15:254-263.
17. Bodineau L., Frugiere A., Marc Y., Inguimbert N., Fassot C., Balavoine F., Roques B., Llorens-Cortes C. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 2008, 51:1318-1325.
18. Bumpus F.M. Angiotensin I and II. Some early observations made at The Cleveland Clinic Foundation and recent discoveries relative to angiotensin II formation in human heart. Hypertension 1991, 18(Suppl. 3):122-125.
19. Bumpus F.M., Catt K.J., Chiu A.T., DeGasparo M., Goodfriend T., Husain A., Peach M.J., Taylor D.J., Timmermans P.B.M.W.M. Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension 1991, 17:720-721.
20. Bunnemann B., Iwai N., Metzger R., Fuxe K., Inagami T., Ganten D. The distribution of angiotensin II AT1 receptor subtype mRNA in the rat brain. Neurosci. Lett. 1992, 142:155-158.
21. Campbell D.J. Angiotensin peptides in the brain. Adv. Exp. Med. Biol. 1995, 377:349-355.
22. Campbell D.J., Duncan A.M., Kladis A., Harrap S.B. Angiotensin peptides in spontaneously hypertensive and normotensive Donryu rats. Hypertension 1995, 25:928-934.
23. Caputo F.A., Scallet A.C. Postnatal MSG treatment attenuates angiotensin II (AII) induced drinking in rats. Physiol. Behav. 1995, 58:25-29.
24. Chai S.Y., McKinley M.J., Mendelsohn F.A. Distribution of angiotensin converting enzyme in sheep hypothalamus and medulla oblongata visualized by in vitro autoradiography. Clin. Exp. Hypertens. [A] 1987, 9:449-460.
25. Chapleau M.W. Modulation of baroreflex function by altering inspiratory impedance: potential mechanisms and clinical implications. Clin. Auton. Res. 2004, 14:217-219.
26. Chappell M. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure?. Hypertension 2007, 50:596-599.
27. Chauvel E.N., Llorens-Cortès C., Coric P., Wilk S., Roques B.P., Fournie-Zaluski M.C. Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols. J. Med. Chem. 1994, 37:2950-2957.
28. Checler F. Neuropeptide-degrading peptidases. Methods in Neurotransmitter and Neuropeptide Research 1993, 375-418. Elsevier Science Publishers, (Chapter 13). S.H. Parvez, M. Naoi, T. Nagatsu (Eds.).
29. Colombari E., Sato M., Cravo S., Bergamaschi C., Campos R.J., Lopes O. Role of the medulla oblongata in hypertension. Hypertension 2001, 38:549-554.
30. Conchon S., Monnot C., Teutsch B., Corvol P., Clauser E. Internalization of the rat AT1a and AT1b receptors: pharmacological and functional requirements. FEBS Lett. 1994, 349:365-370.
31. Cook V.I., Wright J.W., Wright S.A., Harding J.W. Comparison of angiotensin metabolism by brain membranes from SHR and WKY rats. Brain Res. 1990, 529:320-323.
32. Correa F.M., Saavedra J.M. Chemical lesion of the circumventricular organs with monosodium glutamate reduces the blood pressure of spontaneously hypertensive but not of one kidney-one clip hypertensive rats. Braz. J. Med. Biol. Res. 1992, 25:515-519.
33. Corvol P., Jeunemaitre X. Molecular genetics of human hypertension: role of angiotensinogen. Endocr. Rev. 1997, 18:662-677.
34. Corvol P., Plouin P.F. Angiotensin II receptor blockers: current status and future prospects. Drugs 2002, 62:53-64.
35. Culman J., Baulmann J., Blume A., Unger T. The renin-angiotensin system in the brain: an update. J. Renin Angiotensin Aldosterone Syst. 2001, 2:96-102.
36. Czyzewski L.B., Pettinger W.A. Failure of feedback suppression of renin release in the spontaneously hypertensive rat. Am. J. Physiol. 1973, 225:234-239.
37. Dampney R. Functionnal organization of central pathways regulating the cardiovascular system. Physiol. Rev. 1994, 74:323-364.
38. Davisson R.L., Yang G., Beltz T.G., Cassell M.D., Johnson A.K., Sigmund C.D. The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes. Circ. Res. 1998, 83:1047-1058.
39. De Mota N., Itturioz X., Claperon C., Bodineau L., Fassot C., Roques B., Palkovits M., Llorens-Cortes C. Human brain aminopeptidase A: biochemical properties and distribution in brain nuclei. J. Neurochem. 2008, 106:416-428.
40. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000, 52:415-472.
41. Deschepper C.F., Bouhnik J., Ganong W.F. Colocalization of angiotensinogen and glial fibrillary acidic protein in astrocytes in rat brain. Brain Res. 1986, 374:195-198.
42. Diz D.I., Barnes K.L., Ferrario C.M. Contribution of the vagus nerve to angiotensin II binding sites in the canine medulla. Brain Res. Bull. 1986, 17:497-505.
43. Düsing R. Optimizing blood pressure control through the use of fixed combinations. Vasc. Health Risk Manage. 2010, 6:321-325.
44. Eguchi S., Frank G.D., Mifune M., Inagami T. Metalloprotease-dependent ErbB ligand shedding in mediating EGFR transactivation and vascular remodelling. Biochem. Soc. Trans. 2003, 31:1198-1202.
45. Eguchi S., Inagami T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul. Pept. 2000, 91:13-20.
46. Epstein A.N. The physiology of thirst. Can. J. Physiol. Pharmacol. 1976, 54:369.
47. Esler Sympathetic nervous system: contribution to human hypertension and related cardiovascular diseases. J. Cardiovasc. Pharmacol. 1995, 26:S24-S28.
48. Felix D., Schlegel W. Angiotensin receptive neurones in the subfornical organ. Structure-activity relations. Brain Res. 1978, 149:107-116.
49. Feng Y., Xia H., Santos R.A., Speth R., Lazartigues E. Angiotensin-converting enzyme 2: a new target for neurogenic hypertension. Exp. Physiol. 2009, 95:601-606.
50. Ferrario C.M. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 2006, 47:515-521.
51. Fournie-Zaluski M.C., Coric P., Turcaud S., Lucas E., Noble F., Maldonado R., Roques B.P. Potent and systemically active aminopeptidase N inhibitors designed from active site investigation. J. Med. Chem. 1992, 35:1259-1266.
52. Fournie-Zaluski M.C., Fassot C., Valentin B., Djordjijevic D., Reaux-Le Goazigo A., Corvol P., Roques B.P., Llorens-Cortes C. Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:7775-7780.
53. Fried M.R., Eastlund T., Christie B., Mullin G.T., Key N.S. Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor therapy. Transfusion (Paris) 1996, 36:900-903.
54. Ganten D., Fuxe K., Phillips M., Mann J., Ganten U. The brain isorenin-angiotensin system: biochemistry, localization and possible role in drinking and blood pressure regulation. Frontiers in Neuroendocrinology 1978, 5:61-99.
55. Ganten D., Hermann K., Bayer C., Unger T., Lang R.E. Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science 1983, 221:869-871.
56. Ganten D., Minnich J.L., Granger P., Hayduk K., Brecht H.M., Barbeau A., Boucher R., Genest J. Angiotensin-forming enzyme in brain tissue. Science 1971, 173:64-65.
57. Gehlert D.R., Gackenheimer S.L., Schober D.A. Autoradiographic localization of subtypes of angiotensin II antagonist binding in the rat brain. Neuroscience 1991, 44:501-514.
58. Gehlert D.R., Speth R.C., Wamsley J.K. Quantitative autoradiography of angiotensin II receptors in the SHR brain. Peptides 1986, 7:1021-1027.
59. Griendling K.K., Ushio-Fukai M., Lassegue B., Alexander R.W. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997, 29:366-373.
60. Grobe J.L., Xu D., Sigmund C.D. An intracellular renin-angiotensin system in neurons: fact, hypothesis, or fantasy. Physiology (Bethesda) 2008, 23:187-193.
61. Guilluy C., Rolli-Derkinderen M., Loufrani L., Bourge A., Henrion D., Sabourin L., Loirand G., Pacaud P. Ste20-related kinase SLK phosphorylates Ser188 of RhoA to induce vasodilation in response to angiotensin II Type 2 receptor activation. Circ. Res. 2008, 102:1265-1274.
62. Gutkind J.S., Kurihara M., Castren E., Saavedra J.M. Increased concentration of angiotensin II binding sites in selected brain areas of spontaneously hypertensive rats. J. Hypertens. 1988, 6:79-84.
63. Guyenet P. The sympathetic control of blood pressure. Nat. Rev. Neurosci. 2006, 7:335-346.
64. Guyton A.C. Blood pressure control-special role of the kidneys and body fluids. Science 1991, 252:1813-1816.
65. 125I]angiotensin II binding to rat brain membranes. Neurosci. Lett. 1986, 65:23-28.
66. Harding J.W., Felix D. Angiotensin-sensitive neurons in the rat paraventricular nucleus: relative potencies of angiotensin II and angiotensin III. Brain Res. 1987, 410:130-134.
67. Harding J.W., Felix D. The effects of aminopeptidase inhibitors amastatin and bestatin on angiotensin-evoked neuronal activity in rat brain. Brain Res. 1987, 424:299-304.
68. Harding J.W., Jensen L.L., Hanesworth J.M., Roberts K.A., Page T.A., Wright J.W. Release of angiotensins in paraventricular nucleus of rat in response to physiological and chemical stimuli. Am. J. Physiol. 1992, 262:F17-F23.
69. Hatae T., Takimoto E., Murakami K., Fukamizu A. Comparative studies on species-specific reactivity between renin and angiotensinogen. Mol. Cell. Biochem. 1994, 131:43-47.
70. Healy D.P., Wilk S. Localization of immunoreactive glutamyl aminopeptidase in rat brain. II. Distribution and correlation with angiotensin II. Brain Res. 1993, 606:295-303.
71. Hein L., Barsh G.S., Pratt R.E., Dzau V.J., Kobilka B.K. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995, 377:744-747.
72. Hermann K., Raizada M., Sumners C., Phillips M. Presence of renin in primary neuronal and glial cells from rat brain. Brain Res. 1987, 437:205-213.
73. Hersh L.B., Aboukhair N., Watson S. Immunohistochemical localization of aminopeptidase M in rat brain and periphery: relationship of enzyme localization and enkephalin metabolism. Peptides 1987, 8:523-532.
74. Higuchi S., Ohtsu H., Suzuki H., Shirai H., Frank G.D., Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin. Sci. (Lond.) 2007, 112:417-428.
75. Hoffman W.E., Ganten U., Phillips M.I., Schmid P.G., Schelling P., Ganten D. Inhibition of drinking on water-deprived rats by combined central angiotensin II and cholinergic receptor blockade. Am. J. Physiol. 1978, 234:41.
76. Hogarty D.C., Speakman E.A., Puig V., Phillips M.I. The role of angiotensin, AT1 and AT2 receptors in the pressor, drinking and vasopressin responses to central angiotensin. Brain Res. 1992, 586:289-294.
77. Hohle S., Spitznagel H., Rascher W., Culman J., Unger T. Angiotensin AT(1) receptor-mediated vasopressin release and drinking are potentiated by an AT(2) receptor antagonist. Eur. J. Pharmacol. 1995, 275:277-282.
78. Holm E.A., Randlov A., Strandgaard S. Brief report: acute renal failure after losartan treatment in a patient with bilateral renal artery stenosis. Blood Press. 1996, 5:360-362.
79. Hunyady L., Gaborik Z., Vauquelin G., Catt K.J. Structural requirements for signalling and regulation of AT1 receptors. J. Renin Angiotensin Aldosteron Syst. 2001, 2:16-23.
80. Ichiki T., Labosky P.A., Shiota C., Okuyama S., Imagawa Y., Fogo A., Niimura F., Ichikawa I., Hogan B.L.M., Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995, 377.
81. Israili Z.H., Hall W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med. 1992, 117:234-242.
82. Ito S., Sved A. Pharmacological profile of depressor response elicited by sarthran in rat ventrolateral medulla. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:2961-2966.
83. Jamerson K., Weber M.A., Bakris G.L., Dahlof B., Pitt B., Shi V., Hester A., Gupte J., Gatlin M., Velazquez E.J. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008, 359:2417-2428.
84. Johansen T.L., Kjaer A. Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. BMC Nephrol. 2001, 2:1.
85. Johnson A.K., Cunningham J.T., Thunhorst R.L. Integrative role of the lamina terminalis in the regulation of cardiovascular and body fluid homeostasis. Clin. Exp. Pharmacol. Physiol. 1996, 23:183-191.
86. Kambayashi Y., Bardhan S., Takahashi K., Tsuzuki S., Inui H., Hamakubo T., Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 1993, 268:24543-24546.
87. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
88. Kokje R.J., Wilson W.L., Brown T.E., Karamyan V.T., Wright J.W., Speth R.C. Central pressor actions of aminopeptidase-resistant angiotensin II analogs: challenging the angiotensin III hypothesis. Hypertension 2007, 49:1328-1335.
89. Kumar A., Rassoli A., Raizada M.K. Angiotensinogen gene expression in neuronal and glial cells in primary cultures of rat brain. J. Neurosci. Res. 1988, 19:287-290.
90. Lee E.H.Y., Ma Y.L., Wayner M.J., Armstrong D.L. Impaired retention by angiotensin II mediated by the AT(1) receptor. Peptides 1995, 16:1069-1071.
91. Lee-Kirsch M., Gaudet F., Cardoso C., Lindpaintner K. Distinct renin isoforms generated by tissue specific transcription initiation and alternative splicing. Circ. Res. 1999, 84:240-246.
92. 1A predominates in rat forebrain areas involved in blood pressure, body fluid homeostasis and neuroendocrine control. Mol. Brain Res. 1995, 30:53-60.
93. 1B subtype of angiotensin II receptors in the anterior pituitary. Endocrinology 1999, 140:472-477.
94. Lenkei Z., Palkovits M., Corvol P., Llorens-Cortes C. Distribution of angiotensin II type-2 receptor (AT2) mRNA expression in the adult rat brain. J. Comp. Neurol. 1996, 373:322-339.
95. Lenkei Z., Palkovits M., Corvol P., Llorens-Cortes C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front. Neuroendocrinol. 1997, 18:383-439.
96. Lenkei Z., Palkovits M., Corvol P., Llorens-Cortes C. Distribution of angiotensin type-1 receptor (AT1) mRNA expression in the adult rat brain. Neuroscience 1998, 82:827-841.
97. Levine C.B., Fahrbach K.R., Frame D., Connelly J.E., Estok R.P., Stone L.R., Ludensky V. Effect of amlodipine on systolic blood pressure. Clin. Ther. 2003, 25:35-57.
98. Lin K.S., Chan J.Y., Chan S.H. Involvement of AT2 receptors at NRVL in tonic baroreflex suppression by endogenous angiotensins. Am. J. Physiol. 1997, 272:H2204-H2210.
99. Lind R.W., Ganten D. Angiotensin. Handbook of Chemical Neuroanatomy 1990, vol. 9, part II:165-286. Elsevier, Amsterdam.
100. Lind R.W., Swanson L.W., Ganten D. Angiotensin II immunoreactive pathways in the central nervous system of the rat: evidence for a projection from the subfornical organ to the paraventricular nucleus of the hypothalamus. Clin. Exp. Hypertens. 1984, A6:1915-1920.
101. Lind R.W., Swanson L.W., Ganten D. Organization of angiotensin II immunoreactive cells and fibers in the rat central nervous system: an immunohistochemical study. Neuroendocrinology 1985, 40:2-24.
102. Lohmeier T. The sympathetic nervous system and longterm blood pressure regulation. Am. J. Hypertens. 2001, 14:S147-S154.
103. MacGregor D.P., Murone C., Song K., Allen A.M., Paxinos G., Mendelsohn F.A. Angiotensin II receptor subtypes in the human central nervous system. Brain Res. 1995, 675:231-240.
104. Malfroy B., Kado-Fong H., Gros C., Giros B., Schwartz J.C., Hellmiss R. Molecular cloning and amino acid sequence of rat kidney aminopeptidase M: a member of a super family of zinc-metallohydrolases. Biochem. Biophys. Res. Commun. 1989, 161:236-241.
105. Mancia G., Saino A., Grassi G. Interactions between the sympathetic nervous system and the renin angiotensin system. Hypertension: Pathophysiology, Diagnosis, and Management 1995, vols. 1 and 2. pp. 399-407. 2nd edition.
106. Martin M.M., White C.R., Li H., Miller P.J., Elton T.S. A functional comparison of the rat type-1 angiotensin II receptors (AT1AR and AT1BR). Regul. Pept. 1995, 60:135-147.
107. Masuyama Y., Tsuda K., Kuchii M., Nishio I. Peripheral neural mechanism of hypertension in rat models-peripheral sympathetic neurotransmission in hypertension. J. Hypertens. Suppl. 1986, 4:S189-S192.
108. Meng H., Wielbo D., Gyurko R., Phillips M.I. Antisense oligonucleotide to AT1 receptor mRNA inhibits central angiotensin induced thirst and vasopressin. Regul. Pept. 1994, 54:543-551.
109. Meyer J.M., Felten D.L., Weyhenmeyer J.A. Levels of immunoreactive angiotensin II in microdissected nuclei from adult WKY and SH rat brain. Clin. Exp. Hypertens. [A] 1989, 11:103-117.
110. Min L.J., Mogi M., Iwanami J., Li J.M., Sakata A., Fujita T., Tsukuda K., Iwai M., Horiuchi M. Angiotensin II type 2 receptor deletion enhances vascular senescence by methyl methanesulfonate sensitive 2 inhibition. Hypertension 2008, 51:1339-1344.
111. Mitsui T., Nomura S., Okada M., Ohno Y., Kobayashi H., Nakashima Y., Murata Y., Takeuchi M., Kuno N., Nagasaka T., O-Wang J., Cooper M.D., Mizutani S. Hypertension and angiotensin II hypersensitivity in aminopeptidase A-deficient mice. Mol. Med. 2003, 9:57-62.
112. Morimoto S., Cassell M.D., Beltz T.G., Johnson A.K., Davisson R.L., Sigmund C.D. Elevated blood pressure in transgenic mice with brain-specific expression of human angiotensinogen driven by the glial fibrillary acidic protein promoter. Circ. Res. 2001, 89:365-372.
113. Morimoto S., Cassell M.D., Sigmund C.D. Glia- and neuron-specific expression of the renin-angiotensin system in brain alters blood pressure, water intake, and salt preference. J. Biol. Chem. 2002, 277:33235-33241.
114. Morimoto S., Cassell M.D., Sigmund C.D. Neuron-specific expression of human angiotensinogen in brain causes increased salt appetite. Physiol. Genomics 2002, 9:113-120.
115. Morton J.J., Casals-Stenzel J., Lever A.F., Millar J.A., Riegger A.J., Tree M. Inhibitors of the renin-angiotensin system in experimental hypertension, with a note on the measurement of angiotensin I, II and III during infusion of converting-enzyme inhibitor. Br. J. Clin. Pharmacol. 1979, 7:S233-S241.
116. Mukoyama M., Nakajima M., Horiuchi M., Sasamura H., Pratt R.E., Dzau V.J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 1993, 268:24539-24542.
117. Murphy T.J., Alexander R.W., Griendling K.K., Runge M.S., Bernstein K.E. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991, 351:233-236.
118. Nakajima M., Mukoyama M., Pratt R.E., Horiuchi M., Dzau V.J. Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem. Biophys. Res. Commun. 1993, 197:393-399.
119. Naruse M., Naruse K., McKenzie J.C., Schelling P., Inagami T. Regional distribution of renin and angiotensinogen in the brain of normotensive (WKY) and spontaneously hypertensive (SHR) rats. Brain Res. 1985, 333:147-150.
120. Nishimura M., Ohtsuka K., Sakamoto M., Nanbu A., Takahashi H., Yoshimura M. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats. J. Hypertens. 1998, 16:1175-1185.
121. Nouet S., Amzallag N., Li J.M., Louis S., Seitz I., Cui T.X., Alleaume A.M., Di Benedetto M., Boden C., Masson M., Strosberg A.D., Horiuchi M., Couraud P.O., Nahmias C. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J. Biol. Chem. 2004, 279:28989-28997.
122. Nouet S., Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol. Metab. 2000, 11:1-6.
123. Okuyama S., Sakagawa T., Chaki S., Imagawa Y., Ichiki T., Inagami T. Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor. Brain Res. 1999, 821:150-159.
124. Oparil S., Yang R.H., Jin H.G., Chen S.J., Meng Q.C., Berecek K.H., Wyss J.M. Role of anterior hypothalamic angiotensin II in the pathogenesis of salt sensitive hypertension in the spontaneously hypertensive rat. Am. J. Med. Sci. 1994, 307:S26-S37.
125. Owen H.G., Brecher M.E. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion (Paris) 1994, 34:891-894.
126. Palkovits M., Mezey E., Fodor M., Ganten D., Bahner U., Geiger H., Heidland A. Neurotransmitters and neuropeptides in the baroreceptor reflex arc: connections between the nucleus of the solitary tract and the ventrolateral medulla oblongata in the rat. Clin. Exp. Hypertens. 1995, 17:101-113.
127. Palmieri F.E., Bausback H.H., Ward P.E. Metabolism of vasoactive peptides by vascular endothelium and smooth muscle aminopeptidase M. Biochem. Pharmacol. 1989, 38:173-180.
128. Phillips M.I. Functions of angiotensin in the central nervous system. Annu. Rev. Physiol. 1987, 49:413-435.
129. Phillips M.I., Kimura B. Brain angiotensin in the developing spontaneously hypertensive rat. J. Hypertens. 1988, 6:607-612.
130. Porrello E.R., Delbridge L.M., Thomas W.G. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front. Biosci. 2009, 14:958-972.
131. Radevski I., Skudicky D., Candy G., Sathekge S., Strugo V., Sareli P. Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension. Am. J. Hypertens. 1999, 12:194-203.
132. Reaux A., de Mota N., Zini S., Cadel S., Fournie-Zaluski M., Roques B.P., Corvol P., Llorens-Cortes C. PC18, a specific aminopeptidase N inhibitor, induces vasopressin release by increasing the half-life of brain angiotensin III. Neuroendocrinology 1999, 69:370-376.
133. Reaux A., Fournie-Zaluski M.C., David C., Zini S., Roques B.P., Corvol P., Llorens-Cortes C. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:13415-13420.
134. Renaud L.P., Bourque C.W. Neurophysiology and neuropharmacology of hypothalamic magnocellular neurons secreting vasopressin and oxytocin. Prog. Neurobiol. 1991, 36:131-169.
135. Reudelhuber The renin-angiotensin system: peptides and enzymes beyond angioensin II. Curr. Opin. Nephrol. Hypertens. 2005, 14:155-159.
136. Rodrigues-Ferreira S., Nahmias C. An ATIPical family of angiotensin II AT2 receptor-interacting proteins. Trends Endocrinol. Metab. 2010, 21:684-690.
137. Rowe B.P., Grove K.L., Saylor D.L., Speth R.C. Angiotensin II receptor subtypes in the rat brain. Eur. J. Pharmacol. 1990, 186:339-342.
138. Saavedra J.M. Brain and pituitary angiotensin. Endocr. Rev. 1992, 13:329-380.
139. Saine D.R., Ahrens E.R. Renal impairment associated with losartan. Ann. Intern. Med. 1996, 124(8):775.
140. Sakai K., Agassandian K., Morimoto S., Sinnayah P., Cassel M., Davisson R., Sigmund C. Local production of angiotensin II in the subfornical organ causes elevated drinking. J. Clin. Invest. 2007, 117:1088-1095.
141. Sandberg K., Ji H., Clark A.J., Shapira H., Catt K.J. Cloning and expression of a novel angiotensin II receptor subtype. J. Biol. Chem. 1992, 267:9455-9458.
142. Sasaki K., Yamano Y., Bardhan S., Iwai N., Murray J.J., Hasegawa M., Matsuda Y., Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991, 351:230-233.
143. Sasamura H., Hein L., Krieger J.E., Pratt R.E., Kobilka B.K., Dzau V.J. Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem. Biophys. Res. Commun. 1992, 185:253-259.
144. Saunders E.J., Saunders J.A. Drug therapy in pregnancy: the lessons of diethylstilbestrol, thalidomide, and bendectin. Health Care Women Int. 1990, 11:423-432.
145. Schelling P., Meyer D., Loos H.E., Speck G., Phillips M.I., Johnson A.K., Ganten D. A micromethod for the measurement of renin in brain nuclei: its application in spontaneously hypertensive rats. Neuropharmacology 1982, 21:455-463.
146. Schieffer B., Paxton W.G., Marrero M.B., Bernstein K.E. Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling. Hypertension 1996, 27:476-480.
147. Sinn P.L., Sigmund C.D. Identification of three human renin mRNA isoforms from alternative tissue-specific transcriptional initiation. Physiol. Genomics 2000, 3:25-31.
148. Smith D.H. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin. Ther. 2002, 24:1484-1501.
149. Song K., Allen A.M., Paxinos G., Mendelsohn F.A. Mapping of angiotensin II receptor subtype heterogeneity in rat brain. J. Comp. Neurol. 1992, 316:467-484.
150. Song L., Wilk S., Healy D.P. Aminopeptidase A antiserum inhibits intracerebroventricular angiotensin II-induced dipsogenic and pressor responses. Brain Res. 1997, 744:1-6.
151. Speck G., Poulsen K., Unger T., Rettig R., Bayer C., Scholkens B., Ganten D. In vivo activity of purified mouse brain renin. Brain Res. 1981, 219:371-384.
152. Stornetta R.L., Hawelu-Johnson C.L., Guyenet P.G., Lynch K.R. Astrocytes synthesize angiotensinogen in brain. Science 1988, 242:1444-1446.
153. Suzuki H., Motley E.D., Frank G.D., Utsunomiya H., Eguchi S. Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2005, 3:305-322.
154. Swanson L.W., Sawchenko P.E. Hypothalamic integration: organization of the paraventricular and supraoptic nuclei. Annu. Rev. Neurosci. 1983, 6:269.
155. Thomas W.G., Greenland K.J., Shinkel T.A., Sernia C. Angiotensinogen is secreted by pure rat neuronal cell cultures. Brain Res. 1992, 588:191-200.
156. Thomas W.G., Sernia C. Immunocytochemical localization of angiotensinogen in the rat brain. Neuroscience 1988, 25:319-341.
157. Tieku S., Hooper N.M. Inhibition of aminopeptidases N, A and W. A re-evaluation of the actions of bestatin and inhibitors of angiotensin converting enzyme. Biochem. Pharmacol. 1992, 44:1725-1730.
158. Troyanovskaya M., Jayaraman G., Song L., Healy D.P. Aminopeptidase-A. I. CDNA cloning and expression and localization in rat tissues. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 278:R413-R424.
159. Vazeux G., Wang J., Cooper M., Corvol P., Llorens-Cortès C. Identification of glutamate residues essential for catalytic activity and zinc coordination in aminopeptidase A. J. Biol. Chem. 1996, 271:9069-9074.
160. Veerasingham S., Raizada M. Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives. Br. J. Pharmacol. 2003, 139:191-202.
161. Veltmar A., Culman J., Qadri F., Rascher W., Unger T. Involvement of adrenergic and angiotensinergic receptors in the paraventricular nucleus in the angiotensin II-induced vasopressin release. J. Pharmacol. Exp. Ther. 1992, 263:1253-1260.
162. Wan Y., Wallinder C., Plouffe B., Beaudry H., Mahalingam A.K., Wu X., Johansson B., Holm M., Botoros M., Karlen A., Pettersson A., Nyberg F., Fandriks L., Gallo-Payet N., Hallberg A., Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J. Med. Chem. 2004, 47:5995-6008.
163. Watanabe T., Hashimoto M., Okuyama S., Inagami T., Nakamura S. Effects of targeted disruption of the mouse angiotensin II type 2 receptor gene on stress-induced hyperthermia. J. Physiol. 1999, 515(Pt 3):881-885.
164. Welch W.J. Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction. Hypertension 2008, 52:51-56.
165. Wilk S., Healy D.P. Glutamyl aminopeptidase (aminopeptidase A), the BP-1/6C3 antigen. Adv. Neuroimmunol. 1993, 3:195-207.
166. Wilson W. Roles of brain angiotensins in thirst and sodium appetite. Brain Res. 2005, 1060:108-117.
167. Wright J.W., Harding J.W. Regulatory role of brain angiotensins in the control of physiological and behavioral responses. Brain Res. Rev. 1992, 17:227-262.
168. Wright J.W., Harding J.W. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci. Biobehav. Rev. 1994, 18:21-53.
169. Wright J.W., Jensen L.L., Cushing L.L., Harding J.W. Leucine aminopeptidase M-induced reductions in blood pressure in spontaneously hypertensive rats. Hypertension 1989, 13:910-915.
170. Wright J.W., Mitzutani S., Murray C.E., Amir H.Z., Harding J.W. Aminopeptidase-induced elevation and reduction in blood pressure in the spontaneously hypertensive rat. J. Hypertens. 1990, 8:969-974.
171. Wright J.W., Morseth S.L., Abhold R.H., Harding J.W. Pressor action and dipsogenicity induced by angiotensin II and III in rats. Am. J. Physiol. 1985, 249:R514-R521.
172. Wright J.W., Roberts K.A., Cook V.I., Murray C.E., Sardinia M.F., Harding J.W. Intracerebroventricularly infused [D-Arg1]angiotensin III is superior to [D-Asp1]angiotensin II, as a pressor agent in rats. Brain Res. 1990, 514:5-10.
173. Wright J.W., Tamura-Myers E., Wilson W.L., Roques B.P., Llorens-Cortes C., Speth R.C., Harding J.W. Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284:R725-R733.
174. Wright J.W., Yamamoto B.J., Harding J.W. Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets. Prog. Neurobiol. 2008, 84:157-181.
175. Wu Q., Lahti J.M., Air G.M., Burrows P.D., Cooper M.D. Molecular cloning of the murine BP-1/6C3 antigen: a member of the zinc-dependent metallopeptidase family. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:993-997.
176. Yamaguchi K., Negoro H., Hama H., Kamoi K., Sakaguchi T. A comparison between the effects of angiotensin II and angiotensin III injected into the third cerebral ventricle on vasopressin secretion in conscious rats (author's transl). Nippon Naibunpi Gakkai Zasshi 1979, 55:1286-1295.
177. Yamazato M., Yamazato Y., Sun C., Diez-Freire C., Raizada M.K. Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 2007, 49:926-931.
178. Yang C.R., Phillips M.I., Renaud L.P. Angiotensin II receptor activation depolarizes rat supraoptic neurons in vitro. Am. J. Physiol. 1992, 263:R1333-R1338.
179. Yin G., Yan C., Berk B.C. Angiotensin II signaling pathways mediated by tyrosine kinases. Int. J. Biochem. Cell Biol. 2003, 35:780-783.
180. Yongue B.G., Angulo J.A., McEwen B.S., Myers M.M. Brain and liver angiotensinogen messenger RNA in genetic hypertensive and normotensive rats. Hypertension 1991, 17:485-491.
181. Zini S., Demassey Y., Fournie-Zaluski M.C., Bischoff L., Corvol P., Llorens-Cortes C., Sanderson P. Inhibition of vasopressinergic neurons by central injection of a specific aminopeptidase A inhibitor. Neuroreport 1998, 9:825-828.
182. Zini S., Fournie-Zaluski M.C., Chauvel E., Roques B.P., Corvol P., Llorens-Cortes C. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:11968-11973.
183. Zini S., Masdehors P., Lenkei Z., Fournie-Zaluski M.C., Roques B.P., Corvol P., Llorens-Cortes C. Aminopeptidase A: distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats. Neuroscience 1997, 78:1187-1193.